Objective: To evaluate the antihypertensive efficacy, tolcally relevant, dose-related reductions in sitting diastolic blood pressure (SDBP) and sitting systolic blood erability, safety, and dose-response characteristics of the novel calcium antagonist, mibefradil, in combination pressure (SSBP) at trough, which were significantly greater in the 50 and 100 mg dose groups compared to with a diuretic regimen. Design: A multinational, double-blind, randomised, plathe placebo group (P р 0.003). Placebo-corrected treatment effects on SDBP and SSBP at the end of the comcebo-controlled, parallel-design trial. Methods: Three hundred and seven patients whose bined treatment period relative to baseline were, respectively, −4.1 and −8.0 mm Hg in the 50 mg mibeframild-to-moderate essential hypertension remained uncontrolled after 4 weeks of treatment with hydrochlordil group and −9.5 and −8.0 mm Hg in the 100 mg mibefradil group. Therapeutic response rates to combination othiazide (HCTZ) 25 mg/day and placebo were randomised to receive combined treatment with HCTZ and mibefradil and HCTZ therapy were high and dose related, reaching 82% for SDBP in the 100 mg group. once-daily doses of 12.5, 25, 50, or 100 mg of mibefradil or placebo. After 8 weeks of combined treatment, HCTZ Conclusions: The addition of once-daily doses of 50 or 100 mg of mibefradil to patients whose hypertension is was withdrawn and the mibefradil groups continued on their respective doses for an additional 6 weeks. not controlled by HCTZ alone is well tolerated and effective in improving BP control. Results: After 8 weeks, the addition of once-daily doses of mibefradil to the initial HCTZ regimen resulted in cliniKeywords: mibefradil; hydrochlorothiazide; antihypertensives; combination therapy antihypertensive agent may be more effective than Introduction increasing the dose of diuretic. However, patients on Thiazide diuretics, including hydrochlorothiazide chronic diuretic therapy might be more sensitive to (HCTZ), are among the most frequently used drugs the addition of a second antihypertensive because for the treatment of hypertension because they are of volume depletion. Therefore, when evaluating inexpensive and effective in lowering blood pressany new antihypertensive drug, it is important to ure (BP). In addition, they have been documented characterise its efficacy, safety, and tolerability in large prospective trials to reduce cardiovascular when given in combination with a thiazide diuretic. morbidity and/or mortality with long-term treatCalcium antagonists (CAs) are often added to a ment. [1][2][3][4][5] diuretic for patients whose BP remains unconDespite their usefulness, diuretics at increased trolled. Although numerous CAs are available, they doses are associated with numerous undesirable comprise an extremely heterogeneous class of drugs, side effects. In addition to impotence, fatigue, voland there is ongoing controversy as to which of ume depletion, and urinary frequency, metabolic these compounds have relevant additive antihypereffects on serum potassium, glucose, and lipid levels tensive effects with diuretics. [7][8][9][10][11][12] have also been observed. 6 Consequently, for most Mibefradil (Ro 40-5967), a benzimidazolyl-substipatients whose hypertension is unsatisfactorily contuted tetraline derivative, 13 is a novel CA that comtrolled by a low-dose diuretic, prescribing a second bines the desirable properties of high bioavailability (approximately 90%), once-a-day dosing, absence of reflex tachycardia, and the ability to lower heart rate without decreasing myocardial contractility.
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its chemical structure but also by its mechanism of assessments. A complete physical examination was performed at screening and at the last visit. A 12-action. It binds to a unique receptor site 19 and, unlike traditional CAs, selectively blocks T-type callead electrocardiogram (ECG) was recorded at the end of the run-in period, after 4 and 8 weeks of comcium channels. 20 This combination of pharmacokinetic and pharmacodynamic features makes mibbined treatment, and at the final visit. Laboratory evaluations (haematology, chemistry, efradil particularly useful in the treatment of hypertension and angina pectoris. Clinical studies lipid profile, and urinalysis) were performed using blood and urine samples obtained at trough followhave confirmed that mibefradil as monotherapy is effective and well tolerated in the treatment of milding an 8 h fast at screening, at Week 3 of the HCTZ run-in period, at Weeks 4 and 8 of the combined to-moderate essential hypertension and stable angina pectoris when administered once daily at treatment period, and at the final visit. Plasma samples were analysed for mibefradil concendoses of 50 and 100 mg. 21, 22 The present study was designed to determine the trations using a high-pressure liquid chromatography (HPLC) technique. dose-response characteristics and to evaluate the efficacy and safety of mibefradil vs placebo during and after treatment with HCTZ in patients with Statistical analysis mild-to-moderate essential hypertension.
The primary analysis of study parameters was conducted using the intent-to-treat (ITT) population.
Materials and methods
Patients who received one or more doses of randomised trial medication and had a valid baseline SDBP Men and women between the ages of 20 and 70 years with a diagnosis of uncomplicated essential (procedurally correct and performed at 24 ± 3h postdose) and at least one valid post-randomisation hypertension participated in this multinational, double-blind, randomised, parallel-design, placebo-SDBP measurement, were included in the ITT efficacy analyses. In the ITT analyses, patients premacontrolled trial. The study was conducted in 11 countries in accordance with the principles of the turely withdrawn from the study had their last postrandomisation measurements carried forward for Declaration of Helsinki as amended in Tokyo, Venice, and Hong Kong. Local ethics committee evaluation. The primary efficacy parameter was the change in approval was obtained at each of the 20 study sites.
The trial consisted of three periods. During the SDBP from baseline (end of run-in period) to Week 8 of the combined treatment period. The dosefirst period, eligible patients had all current antihypertensive medications withdrawn; they were then response relationship was evaluated using a trend test applying the appropriate linear hypotheses in given 4 weeks of single-blind treatment with 25 mg of HCTZ and placebo, administered once daily.
an analysis of covariance (ANCOVA), with treatment, centre, and treatment-by-centre interaction Patients entered the second period if, after 4 weeks of HCTZ therapy, their predose sitting diastolic BP included as model effects, and baseline SDBP used as a covariate. Pairwise comparisons of each dose (SDBP) remained between 90 and 110 mm Hg, their compliance was at least 80% (capsule counting), group with placebo were performed using the appropriate contrast in the linear model. All statistical and they were tolerating diuretic therapy. Those who qualified were randomised to receive oncetests were two-sided and were performed using an alpha level of 0.05. daily double-blind treatment with placebo or one of four mibefradil doses (12.5, 25, 50, or 100 mg) for 8 Secondary efficacy parameters included the change from baseline to the end of the combined weeks; patients continued to receive once-daily treatment with HCTZ 25 mg during this period. At treatment period (Week 8) in sitting systolic BP (SSBP) at trough, response rates after combined the end of the 8-week combined-therapy period, HCTZ treatment was discontinued and patients treatment, changes in BP at trough following 6 weeks of monotherapy relative to values obtained at remained on their respective placebo or mibefradil treatment for 6 additional weeks.
the end of the combined treatment period, and normalisation rates for SDBP (р90 mm Hg) at the end Excluded from the trial were patients with severe, malignant, or secondary hypertension; major sysof the combined treatment period as well as at the end of the trial. For patients with a baseline SDBP temic disease; body weight Ͼ150% of ideal; or a history of alcohol or drug abuse. Concomitant use of between 90 and 94 mm Hg, response was defined as a reduction from baseline in trough SDBP of у5 medications affecting BP or interfering with the effects of a CA was not allowed during the trial.
mm Hg. For patients with a baseline SDBP between 95 and 110 mm Hg, response was defined as a After screening, patients returned to the clinic at Weeks 3 and 4 of the HCTZ run-in period, after 1, decrease from baseline of у10 mm Hg or normalisation of trough SDBP to р9 mm Hg. Data are 4, and 8 weeks of combined HCTZ and placebo or mibefradil treatment, and after 1 and 6 weeks of plaexpressed as the mean ± standard deviation (s.d.) unless otherwise stated. cebo or mibefradil monotherapy following HCTZ withdrawal. At each visit, BP and heart rate were measured at trough (21-27 h after the previous dose
Results
and before the current day's dose) in the sitting position, and adverse events (AEs); including intercur-A total of 360 patients entered the HCTZ run-in period; 53 failed to meet the eligibility criteria with rent illnesses, were monitored by physical examinations and electrocardiographic and laboratory regard to SDBP or were unable to proceed for admin- istrative or personal reasons. Of the 307 patients who were randomised to receive trial medication, 273 completed the 14-week double-blind treatment period. The placebo and the four mibefradil dose groups were similar with respect to baseline characteristics (Table 1 ). The proportion of males and females was similar in all groups except in the mibefradil 12.5-mg group, where the proportion of males was higher than in the other groups. Twentytwo patients were terminated from the study because of adverse events, five because of inadequate BP control, and seven for other reasons (Table 2) .
With the exception of one patient in the 100-mg mibefradil group who had no post-randomisation efficacy data, data from all randomised patients were included in the ITT efficacy analyses. All randomised patients were included in the safety analysis.
Effects of combined mibefradil and HCTZ therapy
In patients whose BP was not normalised by daily treatment with 25 mg of HCTZ alone, the addition of once-daily doses of 50 or 100 mg mibefradil resulted in clinically meaningful reductions in reductions were statistically significantly greater than those observed in the placebo plus HCTZ group (P р 0.003) (Figure 1 ). The addition of 12.5-and 25-for both SDBP and SSBP (P Ͻ 0.001). Most of the antihypertensive effects of the 50-and 100-mg doses mg doses of mibefradil was not associated with significant changes in SDBP or SSBP compared to plaof mibefradil were achieved during the first week of combined treatment, with only slight further cebo. The linear-trend test across the five treatment groups for the change from the end of the HCTZ rundecreases in SDBP and SSBP observed during the remaining 3 weeks of combined treatment in period to Week 8 of combined mibefradil and HCTZ treatment was highly statistically significant (Figure 2). heart rate in the mibefradil 12.5-, 25-, 50-, and 100-mg dosage groups at the end of the combined treatment period were 0.0, 0.2, −2.2, and −4.8 bpm, respectively. While there would appear to be a clear dose response, the decrease is not statistically significant.
Effects of mibefradil following HCTZ withdrawal
Withdrawal of HCTZ was associated with a slight increase in SDBP in all groups (4.5, 4.0, 1.8, 3.2, and 1.5 mm Hg for placebo, mibefradil 12.5 mg, 25 mg, 50 mg, and 100 mg, respectively). A similar effect was noted for SSBP (Figure 4) . At the end of the study, the normalisation rates of SDBP achieved in the 12.5-, 25-, 50-, and 100-mg mibefradil groups (26%, 35%, 43%, and 76%, respectively) were higher than that of the placebo group (18%). Cessation of HCTZ treatment had negligible effects on heart rate. Mean changes in sitting heart rate from the end of the combined treatment period to the end of the 6-week HCTZ withdrawal period 
Safety and tolerability
Tolerability: The overall incidence of adverse The proportion of patients demonstrating a theraevents across the 14-week double-blind treatment peutic response to combined mibefradil and HCTZ period, as well as the incidence of AEs judged by therapy after 8 weeks was clearly dose related, the investigators to be at least remotely related to increasing from 32% in the placebo plus HCTZ trial medication ('treatment-related AEs'), were very group, to 82% in the 100-mg mibefradil plus HCTZ similar in all treatment groups (Table 3) . Leg oedema group (Figure 3 ). The response rates observed in the was the only AE that was more frequent in the mib-50-and 100-mg mibefradil groups were significantly efradil 100-mg dose group (6%) than in any other greater than those observed in the placebo group (P group (2% to 3%). In all mibefradil treatment Ͻ 0.01 for both groups).
groups, the rate of premature withdrawal due to AEs The placebo-corrected treatment effects on sitting was either similar to or lower than that in the placebo group (Table 2) . Worsening of hypertension was the leading AE responsible for premature withunchanged mibefradil during the combination treatment period were similar to those observed during drawal; it was reported in three, two, one and one patients receiving placebo, 12.5, 25, and 100 mg of the HCTZ withdrawal period (ie, mibefradil monotherapy) (Table 4) . mibefradil, respectively.
ECG findings:
At the end of the trial, mibefradil treatment was associated with a dose-dependent Discussion reduction in heart rate that ranged from −1.8 ± 14.6 bpm with the 12.5-mg dose to −8.9 ± 8.5 bpm with
The results of this trial clearly demonstrate that the addition of once-daily doses of 50 or 100 mg mibefthe 100-mg dose. A slight dose-related increase in the PQ interval that averaged 10.6 ± 19.4 msec was radil to the diuretic regimen of patients whose BP was not controlled by HCTZ 25 mg alone resulted in observed in the 100-mg dosage group. Sinus bradycardia (heart rate Ͻ55 bpm with a change from baseclinically relevant and statistically significant reductions in diastolic and systolic BP in compariline of у10 bpm) and first-degree atrioventricular (AV) block (PQ interval Ͼ200 msec) were the most son with placebo. Doses of 12.5 and 25 mg of mibefradil combined with HCTZ 25 mg did not result in common treatment-emergent ECG changes in the mibefradil groups (Table 3 ). The remaining ECG clinically relevant reductions in BP. The magnitude of the effects induced by the 50-and 100-mg doses changes were sporadically distributed among the dose groups, and none were judged to be of a serious of mibefradil in this study were similar to those observed in the dose-finding study reported by nature. Only one patient in the 50-mg mibefradil group was withdrawn because of sinus bradycardia Bernink et al 21 in patients receiving mibefradil alone for the treatment of mild-to-moderate hypertension. (heart rate of 50 bpm) associated with dizziness, and one patient in the placebo group was discontinued Similarly, the present study also found that the effect of the 25-mg dose of mibefradil was no differbecause of atrial fibrillation. ent than that of placebo. Patients on diuretic therapy could be more sensiLaboratory results, including plasma lipids: The addition of mibefradil 50 or 100 mg to HCTZ did not tive to the addition of a CA which acts to lower BP primarily through peripheral vasodilation. Neverresult in relevant changes in serum lipid profile, including triglycerides, total cholesterol, low-dentheless, such sensitivity was not observed in this study and the ineffectiveness of the 25-mg dose indisity lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and very-low-density cates that, in the population studied, the lowest effective dose of mibefradil is 50 mg. Therefore, lipoprotein (VLDL) cholesterol at Week 8 ( Figure 5 ). There was no consistent pattern of mean changes or among patients whose BP was not controlled with HCTZ 25 mg/day, there was no enhanced sensitivity individual abnormalities for the remaining haematology, chemistry, or urinalysis parameters during to the BP lowering activity of mibefradil. No cases of postural hypotension or first-dose hypotension were this trial. One patient in the 50-mg mibefradil dosage group was withdrawn 16 days after randomisobserved as might be the case when some drugs such as an ACE inhibitor are added to chronic diuretic ation because of elevations in serum levels of liver enzymes; these changes were already evident during therapy. 23 The statistically significant linear dose trend the HCTZ run-in period and were thought to be a possible consequence of diuretic therapy, even observed for both SDBP and SSBP in this trial indicates that increased doses of mibefradil during though hepatic adverse drug reactions are rare with diuretics.
HCTZ therapy are associated with improvements in the magnitude of BP control. After 8 weeks of combination therapy, response rates were high, reaching Plasma concentrations of mibefradil: Within each dose group, mean trough concentrations of 82% for patients receiving daily treatment with No pharmacokinetic interaction was apparent between mibefradil and HCTZ. Plasma trough concentrations of unchanged mibefradil at steady state were comparable during combination therapy with HCTZ and during mibefradil monotherapy after withdrawal of HCTZ, and were also similar to those reported by Bernink et al 21 and Bakx et al 22 in patients receiving mibefradil monotherapy at similar doses.
Cessation of HCTZ therapy resulted in a small but clear increase in SDBP and SSBP in all treatment groups, suggesting that the treatment with HCTZ 25 mg contributed to the antihypertensive efficacy of the mibefradil-HCTZ combination. The magnitude of the effect of HCTZ in the present population cannot be precisely evaluated because of the lack of baseline measurements prior to HCTZ treatment. Nevertheless, based on the slight increase in BP observed after HCTZ withdrawal and the continued high response rates after 6 weeks of mibefradil monotherapy (76% in the mibefradil 100-mg dose group); it appears that the contribution of HCTZ to the control of BP in these patients was modest.
Previous studies have reported conflicting results for the additive potential of a thiazide diuretic and a calcium antagonist. [7] [8] [9] [10] [11] [12] The observations of the present trial cannot be extrapolated to the general hypertensive population because patients were selected for this study based on their insufficient response to therapy with HCTZ 25 mg. Therefore, further studies using more appropriate designssuch as a factorial design -will be required to evaluate the true contribution of each component to the mibefradil-HCTZ combination. 24 When such a factorial design study was undertaken to examine the interaction between diltiazem and HCTZ, the additive antihypertensive effects of the drug combination were clearly demonstrated.
12 Combination HCTZ plus mibefradil therapy cannot be recommended as first-line treatment over mibefradil onists have been shown to produce diuresis and natriuresis 25 without impairing renal function. This effect occurs independently of the hypotensive response and appears to be long term and persistent. mibefradil 100 mg plus HCTZ 
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